How to Choose Frontline Therapy for Chronic Myelogenous Leukemia: So Many Drugs, Not So Many Patients

Author: Paul J. Shami MD 1
View More View Less
  • 1 From the Division of Hematology and Hematologic Malignancies, University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah.

With the development of tyrosine kinase inhibitors (TKIs), the management and outlook for patients with chronic myelogenous leukemia (CML) have completely changed over the past 10 years. Imatinib was the first TKI approved to treat CML in the chronic phase. After their initial approval as second-line agents, dasatinib and nilotinib were compared with imatinib in the first-line setting in 2 randomized trials. Both trials showed that therapeutic milestones (complete cytogenetic remission and major molecular remission) occurred earlier with these newer agents, leading to their approval for the treatment of newly diagnosed CML. Therefore, 3 different TKIs are now available for treating CML. Long-term follow-up of patients treated with imatinib shows that the attainment of therapeutic milestones by 12 months of therapy leads to better long-term outcomes. Most patients who experience disease progression on imatinib do so within the first 3 years of therapy. Therefore, one can argue that dasatinib or nilotinib should be chosen to treat patients with newly diagnosed CML. However, these agents do not have the long-term track record of imatinib. This article summarizes the published data and reviews the rationale in choosing the appropriate TKI for first-line treatment of CML in the chronic phase.

Medscape: Continuing Medical Education Online

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and JNCCN- The Journal of the National Comprehensive Cancer Network. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at; (4) view/print certificate.

Release date: January 6, 2012; Expiration date: January 6, 2013.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe similarities and differences of imatinib, nilotinib, and dasatinib, based on a review
  • Describe the case for the use of imatinib in first-line therapy of CML, based on a review
  • Describe the case for the use of dasatinib or nilotinib in first-line therapy of CML, based on a review

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder resulting from a translocation between chromosomes 9 and 22 (t(9;22) or Philadelphia chromosome) leading to an abnormal fusion protein (BCR-ABL) with dysregulated tyrosine kinase activity.1 Without therapy, CML has a predictable progression from a chronic phase (CP) to the more advanced accelerated (AP) and blast (BP) phases. Although it is a rare disease, with an estimated incidence of 4870 in the United States in 2010,2 it has occupied a substantial portion of the medical literature over the past 10 years because of the development of highly successful tyrosine kinase inhibitors (TKIs) that have changed the treatment paradigm. In fact, attempts to follow a similar strategy for other malignancies has become the main focus of cancer drug development, although with less spectacular results. Three TKIs have received regulatory approval to treat CML. Imatinib was the first agent to be approved, and established a change in the standard of care. Dasatinib and nilotinib were then developed as second-line agents for imatinib failures. They are both active against most ABL tyrosine kinase domain mutations that impart resistance to imatinib. As expected, the second-generation TKIs were ultimately tested in the first-line setting and have now received regulatory approval for that indication. This article reviews the data on the drugs to determine the best approach to choosing a firstline agent for patients with CP-CML.

The Facts

Several clinical trials that changed the treatment paradigm and outlook for patients with CML were reported over approximately 10 years. This article reviews some of the most relevant trials evaluating the use of TKIs in first-line therapy.


The International Randomized Study of Interferon and STI571 (IRIS) study established imatinib as the standard of care for CP-CML.3 This study randomly assigned 1106 patients to receive either the combination of interferon-α and low-dose cytarabine (IFN-α/Ara-C; the standard of care at that time) or imatinib at a dose of 400 mg daily. At a median follow-up of 19 months, the rates of complete cytogenetic response (CCyR) at 18 months were 76.2% and 14.5% in the imatinib and IFN-α/Ara-C arms, respectively. At 18 months, the rates of freedom from disease progression were estimated to be 96.7% and 91.5%, respectively. Imatinib was significantly better tolerated, with only 14.3% of patients discontinuing therapy or crossing over to the alternative arm, as opposed to 89.2% for IFN-α/Ara-C.

A 6-year update on the patients randomized to the imatinib arm confirmed these outstanding results.4 The cumulative best CCyR rate was 82%, with 63% of patients who were still on imatinib in CCyR. The estimated event-free survival was 83%, with an overall survival rate of 88%. The rate of freedom from progression to AP or BP was estimated to be 93%. Follow-up of the imatinib arm at 8 years showed that outcomes continued to be very good, with 82% of patients in CCyR and 92% of patients still free from progression to AP or BP.5 The highest risk of loss of response or transformation was during the first 3 years of treatment (3.3%-7.5%), and decreased thereafter.

Hammersmith Hospital

Subsequently, investigators from Hammersmith Hospital reported their experience using imatinib in the first-line treatment of 204 patients with CP-CML.6 At 5 years, the cumulative incidence of CCyR was 82.7%, with an estimated overall survival rate of 83.2%. The progression-free survival rate was estimated to be 82.7%. However, 25% of patients had discontinued therapy because of unsatisfactory response or side effects. As a result, the probability of remaining on therapy at 5 years while maintaining a major cytogenetic response was only 62.7%.

The Real World

In a population-based study from the United Kingdom, Lucas et al.7 reported their experience using imatinib, 400 mg daily, as first-line therapy in the treatment of 68 patients with CP-CML. Of these, 3 progressed to BP within the first 12 months of therapy. During that same period, 2 patients experienced toxicity serious enough to warrant alternative therapy, and 1 patient lost complete hematologic response. The CCyR rates were 41%, 49%, and 51% at 24 months, imatinib treatment failed in 49% of patients because of progression to BP, failure to experience or maintain CCyR, or intolerance. These results suggest that, in a general practice setting, outcomes with imatinib therapy may not be as good as what was observed in the IRIS study.

High-Dose Imatinib

Two randomized trials were conducted comparing high-dose and standard-dose imatinib in the treatment of CP-CML. The Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study randomized 476 patients with newly diagnosed CML to either 400 or 800 mg of imatinib daily. At 6 months of therapy, rates of major molecular response (MMR; defined as a 3-log reduction in copy number of BCR-ABL transcripts, 0.1% or lower on the international scale) and CCyR were higher in the high-dose arm.8 However, at 12 months they were comparable (46% vs. 40% and 70% vs. 66% for high-dose and standard-dose imatinib, respectively). Furthermore, no difference was seen in progression-free and overall survival rates between the arms at 18 months (97.4% vs. 95.0% and 98.7% vs. 98.2%, respectively).

The German CMLIV trial also reported faster responses with 800 mg of imatinib (administered on a tolerability-adapted schedule) than with 400 mg of imatinib or the combination of imatinib and IFN-α.9 However, no difference was seen in overall and progression-free survival rates (92% and 88%, respectively) at 5 years between the treatment arms. Notably, in the 800-mg arm, the median dose that was administered on the tolerability-adapted schedule was only 628 mg/d.

Imatinib-Based Drug Combinations

It was expected that imatinib would ultimately be combined with the older agents in an attempt to improve outcomes, and 2 large randomized trials of this strategy were conducted. The German CMLIV study randomized patients with CP-CML to either imatinib at 400 mg/d, imatinib at 800 mg/d, or the combination of imatinib and IFN-α. Responses in the high-dose imatinib arm were higher than in both of the other arms with no differences in progression-free or overall survival.9 However, no differences were seen in CCyR and MMR between the standard-dose imatinib and the imatinib/IFN-α arms. At 12 months, the rates of CCyR and MMR were 49% and 31%, respectively, for imatinib at 400 mg, and 50% and 35%, respectively, for imatinib/IFN-α. At 24 months, these rates were 74% and 63%, and 77% and 63%, respectively.

The French SPIRIT trial randomized patients with CP-CML to 1 of 4 arms, namely imatinib at 400 mg or 600 mg daily, or the combination of imatinib (400 mg daily) with cytarabine or pegylated IFN. At 12 months, the combination of imatinib and pegylated IFN led to a higher rate of MMR than was seen in the other arms.10 However, no difference was seen in CCyR. At that time point, rates of CCyR were 58%, 65%, 70%, and 66% for the imatinib, 400 mg; imatinib, 600 mg; imatinib/cytarabine; and imatinib/IFN arms, respectively. Rates of MMR were 38%, 49%, 46%, and 57%, respectively. Adverse events were more common with IFN than with imatinib, 400 mg. In both the CMLIV and the SPIRIT trials, the rates of transformation-free and overall survival were not improved by the addition of IFN.


After its approval as a second-line agent, and with promising results from phase II studies in the first-line setting,11,12 nilotinib was compared with imatinib in a randomized fashion for the treatment of patients with newly diagnosed CP-CML. The ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients) was a randomized study that enrolled 846 patients to 1 of 3 arms: nilotinib at 300 mg or 400 mg twice daily, or imatinib at 400 mg once daily.13 The primary end point of the study was MMR at 12 months. The rates of MMR at that time point were 44%, 43%, and 22% for the nilotinib, 300 mg; nilotinib, 400 mg; and imatinib arms, respectively. The rates of CCyR were 80%, 78%, and 65%, respectively. The superiority of nilotinib over imatinib was observed in all risk groups, including patients with high Sokal risk scores.

The trends were confirmed at 24 months when the rates of BCR-ABL reduction to 0.0032% or less were 26%, 21%, and 10% for the 3 arms, respectively.14 Importantly, a statistically significant lower rate of progression to AP/BP was seen in the nilotinib arms as opposed to the imatinib arm. After 24 months of follow-up, these rates were 0.7%, 1.1%, and 4.2% in the nilotinib, 300 mg; nilotinib, 400 mg; and imatinib arms, respectively.14 Nilotinib was generally better tolerated, particularly in terms of hematopoietic, musculoskeletal, and gastrointestinal toxicity. However, grade 3/4 abnormalities in alanine aminotransferase, bilirubin, lipase, and glucose were more frequent with nilotinib treatment. Dermatologic events and headaches were also more frequent with nilotinib. Despite previous concerns regarding the effect of nilotinib on the QT interval, no patient on nilotinib developed QTc prolongation to an interval greater than 500 ms at the 24-month data cutoff point.15 Nor was a decrease lower than 45% observed in the mean ventricular ejection fraction. After these results, the FDA approved nilotinib for the treatment of patients with newly diagnosed CP-CML.


Similar to nilotinib, phase II data showed promising results for dasatinib in the first-line setting.16 It was therefore subsequently compared with imatinib in a randomized trial. The DASISION trial (Dasatinib Versus Imatinib Study In Treatment-naïve CML) randomized 519 patients to either dasatinib at 100 mg daily, or imatinib at 400 mg daily. The primary end point was a confirmed CCyR (2 measurements) at 12 months. The CCyR rates at 12 months were 66% and 77% for imatinib and dasatinib, respectively.17,18 When compared based on at least 1 measurement, the CCyR rates were 72% and 83% for imatinib and dasatinib, respectively. At 12 months, the rates of MMR were 28% and 46%, respectively, and at 24 months were 46% and 64%, respectively. Development of AP/BP at 12 months occurred in 1.9% of patients treated with dasatinib and 3.5% in patients treated with imatinib. However, the latter differences were not statistically significant. At 24 months, the rates of disease progression were 2.4% and 5.0% for dasatinib and imatinib, respectively. Again these differences were not statistically significant. At 24 months, 17% of patients treated with dasatinib had achieved a BCR-ABL transcript level below 0.0032%, compared with 8% of patients treated with imatinib. Thrombocytopenia was more common with dasatinib, whereas neutropenia occurred at equal frequency. Edema, nausea, vomiting, and rashes were more common with imatinib. In earlier studies, pleural effusions were seen in patients treated with dasatinib, particularly at a dose of 70 mg twice daily.19,20 In the DASISION study, no pleural effusions were observed in the imatinib arm. In the dasatinib arm, pleural effusions occurred in 14% of patients. These were mainly grade 1 and 2, with fewer than 1% of patients developing grade 3 pleural effusions.21 Notably, a randomized phase II intergroup study was subsequently reported in which patients with CP-CML were assigned to either imatinib 400 mg/d or dasatinib 100 mg/d.22 At 12 months, the rates of CCyR and MMR were 69% and 32% in the imatinib arm and 82% and 47% in the dasatinib arm, respectively.

Early Responses and Long-Term Outcomes

As could be expected, most of the data on the impact of early responses on long-term outcomes are from the IRIS study. Patients who fared the best in the IRIS study were those who had experienced both a CCyR and an MMR at 12 months. None of those patients' disease had progressed to AP or BP by 5 years of therapy, compared with a 5% rate of disease progression in patients who had experienced a CCyR but not an MMR at 12 months.23,24 Another analysis of the IRIS data showed that the earlier patients experienced a CCyR (3, 6, 12, or 18 months), the better their long-term outcomes.5 Most patients in the IRIS trial who experienced disease progression while on imatinib did so during the first 3 years of therapy.5

Similar trends were seen in the long-term analysis of the Hammersmith data. In that study, patients who experienced a CCyR at 12 months showed substantially better transformation-free and overall survival rates at 5 years than patients who did not (96% vs. 74%, and 98% vs. 74%, respectively).6 However, in this series, experiencing an MMR at 12 months did not convey a long-term advantage.

Peculiarities of Each Approved TKI

Although imatinib, nilotinib, and dasatinib share a common mechanism of action, namely tyrosine kinase inhibition, they have important differences. From a mechanistic standpoint, both imatinib and nilotinib bind to an inactive conformation of the ABL kinase, whereas dasatinib binds to multiple conformations.25,26 Nilotinib is up to 50 times more potent than imatinib at inhibiting BCR-ABL in cell proliferation assays, whereas dasatinib is up to 325 times more potent.23,27 Of the 3 agents, nilotinib is the least promiscuous in its ability to inhibit different tyrosine kinases. Dasatinib is a dual BCR-ABL and SRC kinase inhibitor.

ABL kinase domain mutations constitute the most common mechanism of resistance to imatinib. More than 50 of these mutations have been described.28 Both dasatinib and nilotinib are active against all known imatinib-resistant mutations, except the T315I mutation, which imparts resistance to all 3 agents. However, dasatinib and nilotinib have differences in their potency against specific non-T315I mutations.27

From a toxicity standpoint, all 3 agents are generally well tolerated. However, a few points are significant regarding nonhematologic toxicity. Diarrhea, fluid retention, and muscle cramps are more common with imatinib than with nilotinib or dasatinib.13,17 Although these are generally tolerable (mainly grade 1/2), they can become problematic in the long run from a quality-of-life standpoint. This is particularly relevant in view of the expected long-term survival of patients in the TKI era.

In the early development of nilotinib, unexplained sudden deaths were reported, which led to a black box warning on its label. However, in the ENESTnd trial, no sudden deaths occurred in the nilotinib arms, and no patient on nilotinib had a prolongation of the QTc interval greater than 500 ms.17 Furthermore, QTc prolongation seems to be a class effect for these agents.

Again, in its early development, dasatinib was associated with a substantial incidence of pleural effusions. Clinically relevant pleural effusions were seen more commonly at doses of 70 mg twice daily than with the now-adopted regimen of 100 mg daily.19,20 In the DASISION study, patients were closely monitored for the development of pleural effusions. Although 14% of patients in the dasatinib arm developed pleural effusions, fewer than 1% of these were grade 3.21

Expansion of clonal cytotoxic T or natural killer (NK) cells has been described in patients treated with dasatinib.29-34 In the DASISION trial, lymphocytosis occurred in 5% and 24% of patients treated with imatinib or dasatinib, respectively. Patients on dasatinib who developed lymphocytosis had a higher rate of CCyR at 12 months than those who did not develop lymphocytosis (84% vs. 75%). Lymphocytosis in patients treated with dasatinib was also associated with a higher incidence of pleural effusions (18% vs. 8%). Whether lymphocytosis contributes to dasatinib's antileukemic effects through an immunomodulatory mechanism is yet to be proven.

The Case for the Use of Imatinib in First-Line Therapy

Imatinib is clearly a very active drug. One can therefore make a strong argument to continue using it in the first-line setting. Imatinib has been approved for 10 years, and most patients who were started on it in the first-line setting are alive and doing well. Therefore, imatinib has a proven track record for a sustained response lasting at least several years. Dasatinib and nilotinib do not have such a long track record. Furthermore, imatinib is generally well tolerated. Most of its nonhematologic side effects, such as diarrhea and peripheral edema, are of grade 1 or 2. Finally, with proper monitoring of disease response using current molecular techniques, one should be able to identify patients with loss of response early on and switch them to dasatinib or nilotinib. Similar to imatinib, the latter agents are not active against the T315I mutation, for which an allogeneic stem cell transplant is still the preferred treatment until agents with an even broader spectrum of activity are approved.

The Case for the Use of Dasatinib or Nilotinib in First-Line Therapy

Although imatinib is an excellent drug based on the IRIS data, the Hammersmith data and the study by Lucas et al.7 suggest that long-term results are not as favorable. Based on the Hammersmith data, roughly one-third of patients will not have the response that one would hope for. The data reported by Lucas et al.7 suggest that only approximately half of the patients treated with imatinib in a community setting would be expected to have a sustained positive outcome. Imatinib is generally well tolerated. Certainly, if it is compared with IFN-α, then its side-effect profile is very favorable. However, although most of its nonhematologic side effects are grade 1 or 2, they could significantly affect quality of life in the long run. For instance, if given the choice, most patients would certainly want to avoid a lifetime of grade 1/2 diarrhea.

The most important argument in favor of using dasatinib or nilotinib in first-line therapy is the fact that with both agents, the response milestones (CCyR and MMR) are achieved earlier and in more patients than with imatinib. Long-term follow-up data clearly show that patients who achieve these milestones earlier have the best outcomes. The IRIS data suggest that once a TKI is started, there is a window of 2 to 3 years during which the risk of disease progression or transformation is highest. The ENESTnd and DASISION studies strongly suggest that nilotinib and dasatinib decrease the risk of disease progression, certainly up to the point of analysis. This outcome is not unexpected, because they have a broader spectrum of activity as far as resistanceimparting mutations are concerned. Although a blast transformation has become a relatively rare event in the TKI era, this outcome is devastating for patients. Casting a wider net with dasatinib or nilotinib to diminish the risk of disease progression early on is certainly a sound strategy. These agents do not have the track record of sustained response that imatinib has. Technically, one cannot extrapolate to dasatinib and nilotinib the observations on the 2- to 3-year “window of opportunity” that have been made with imatinib. However, currently no data suggest that they would not be similar in that respect. Finally, based on available data, one could predict that fewer patients started on dasatinib or nilotinib will require salvage therapy than those started on imatinib.

What To Do?

Compared with 10 years ago, hematologists treating patients with CML have the enviable problem of having to choose among 3 outstanding agents. Based on recent studies, it is clearly justified to start dasatinib or nilotinib in patients with newly diagnosed CPCML, particularly those with high-risk disease. The recent report of the NCCN Task Force on the use of TKIs in the treatment of CML states that imatinib continues to be a reasonable choice for patients with low-risk Sokal or Hasford scores, but strongly recommends the use of dasatinib or nilotinib for those with intermediate- or high-risk scores.35 However, one must individualize the decision for each patient based on comorbidities, drug interactions, and lifestyle. Nilotinib may not be a good choice for patients whose lifestyle prevents them from having to take an oral medication twice a day on an empty stomach. Nor may it be a good choice for patients with a history of pancreatitis. Likewise, dasatinib may not be a good choice for patients who need to take a proton pump inhibitor on a sustained basis. Nor may it be a good choice for patients who have a history of congestive heart failure or pleural effusions.

Pharmacoeconomic considerations are likely to become more significant in a few years when imatinib is expected to go off-patent. However, even though the hematologist's task in treating CML has become more complicated, patients with CML now are in a much better position and have a much better outlook than just a few years ago.


Kerrin M. Green, MA, Assistant Managing Editor, Journal of the NationalComprehensive Cancer Network

Disclosure: Kerrin M. Green, MA, has disclosed no relevant financial relationships.


Paul J. Shami, MD, Division of Hematology and HematologicMalignancies, University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah

Disclosure: Paul J. Shami, MD, has disclosed the following relevant financial relationships: Serves on advisory boards and a speaker's bureau for: Novartis Pharmaceuticals Corporation


Laurie Barclay, MD, Freelance writer and reviewer, Medscape, LLC

Disclosure: Laurie Barclay, MD, has disclosed no relevant financialrelationships.


  • 1

    Faderl S, Talpaz M, Estrov Z. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.

  • 2

    SEER Stat Fact Sheets: Chronic Myeloid Leukemia. National Cancer Institute Surveillance Epidemiology and End Results Web site. Available at: Accessed November 30, 2011.

    • Search Google Scholar
    • Export Citation
  • 3

    O'Brien SG, Guilhot F, Larson RA. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.

    • Search Google Scholar
    • Export Citation
  • 4

    Hochhaus A, O'Brien SG, Guilhot F. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-1061.

    • Search Google Scholar
    • Export Citation
  • 5

    Deininger M, O'Brien SG, Guilhot F. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract]. Blood 2009;114:462. Abstract 1126.

    • Search Google Scholar
    • Export Citation
  • 6

    de Lavallade H, Apperley JF, Khorashad JS. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.

    • Search Google Scholar
    • Export Citation
  • 7

    Lucas CM, Wang L, Austin GM. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008;22:1963-1966.

    • Search Google Scholar
    • Export Citation
  • 8

    Cortes JE, Baccarani M, Guilhot F. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28:424-430.

    • Search Google Scholar
    • Export Citation
  • 9

    Hehlmann R, Lauseker M, Jung-Munkwitz S. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-1642.

    • Search Google Scholar
    • Export Citation
  • 10

    Preudhomme C, Guilhot J, Nicolini FE. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-2521.

  • 11

    Rosti G, Palandri F, Castagnetti F. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009;114:4933-4938.

  • 12

    Cortes JE, Jones D, O'Brien S. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392-397.

    • Search Google Scholar
    • Export Citation
  • 13

    Saglio G, Kim DW, Issaragrisil S. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.

  • 14

    Hochhaus A, Saglio G, le Coutre P. Superior efficacy of nilotinib compared with imatinib in newly-diagnosed patients with chronic myeloid leukemia in chronic (CML-CP): ENESTnd minimum 24-month follow-up [abstract]. Haematologica 2011;96(Suppl 2):Abstract 0484.

    • Search Google Scholar
    • Export Citation
  • 15

    Hughes TP, Hochhaus A, Saglio G. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood 2010;116:Abstract 207.

    • Search Google Scholar
    • Export Citation
  • 16

    Cortes JE, Jones D, O'Brien S. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404.

    • Search Google Scholar
    • Export Citation
  • 17

    Kantarjian H, Shah NP, Hochhaus A. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.

    • Search Google Scholar
    • Export Citation
  • 18

    Hochhaus A, Shah N, Cortes J. Efficacy and safety of dasatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): minimum 24-month follow-up from the DASISION trial [abstract]. Haematologica 2011;96(Suppl 2):Abstract 1011.

    • Search Google Scholar
    • Export Citation
  • 19

    Quintás-Cardama A, Kantarjian H, O'Brien S. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-3914.

    • Search Google Scholar
    • Export Citation
  • 20

    Shah NP, Kantarjian HM, Kim DW. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronicphase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212.

    • Search Google Scholar
    • Export Citation
  • 21

    Porkka K, Baccarani M, Cortes J. Pleural effusion in patients with chronic-phase chronic myeloid leukemia (CML-CP) who received first-line dasatinib in the DASISION trial: patient characteristics, management, and outcomes [abstract]. Haematologica 2011;96(Suppl 2):Abstract 0692.

    • Search Google Scholar
    • Export Citation
  • 22

    Radich JP, Kopecky KJ, Kamel-Reid S. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial [abstract]. Blood 2010;116:Abstract LBA6.

    • Search Google Scholar
    • Export Citation
  • 23

    Druker BJ, Guilhot F, O'Brien SG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.

    • Search Google Scholar
    • Export Citation
  • 24

    Baccarani M, Guilhot F, Larson RA. Outcomes by cytogenetic and molecular response at 12 and 18 months of imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) in the IRIS trial [abstract]. Blood 2006;108:606a. Abstract 2138.

    • Search Google Scholar
    • Export Citation
  • 25

    Weisberg E, Manley PW, Breitenstein W. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-141.

    • Search Google Scholar
    • Export Citation
  • 26

    Tokarski JS, Newitt JA, Chang CY. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-5797.

    • Search Google Scholar
    • Export Citation
  • 27

    O'Hare T, Walters DK, Stoffregen EP. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505.

    • Search Google Scholar
    • Export Citation
  • 28

    Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-1029.

  • 29

    Kreutzman A, Juvonen V, Kairisto V. Mono/oligoclonal T- and NK-cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-782.

    • Search Google Scholar
    • Export Citation
  • 30

    Nagata Y, Ohashi K, Fukuda S. Clinical features of dasatinibinduced large granular lymphocytosis and pleural effusion. Int J Hematol 2010;91:799-807.

    • Search Google Scholar
    • Export Citation
  • 31

    Mustjoki S, Ekblom M, Arstila TP. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-1405.

    • Search Google Scholar
    • Export Citation
  • 32

    Kim DH, Kamel-Reid S, Chang H. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009;94:135-139.

    • Search Google Scholar
    • Export Citation
  • 33

    Schiffer CA, Cortes JE, Saglio G. Association of lymphocytosis following treatment with dasatinib with response and outcome [abstract]. J Clin Oncol 2010;28(15 Suppl):Abstract 6553.

    • Search Google Scholar
    • Export Citation
  • 34

    Schiffer CA, Cortes JE, Saglio G. Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib [abstract]. Blood 2010;116:Abstract 358.

    • Search Google Scholar
    • Export Citation
  • 35

    O'Brien S, Berman E, Moore JO. NCCN Task Force Report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011:9(Suppl 2):S1-25.

    • Search Google Scholar
    • Export Citation

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Paul J. Shami, MD, Division of Hematology and Hematologic Malignancies, University of Utah, Suite 2100- Huntsman Cancer Institute, Salt Lake City, UT 84112. E-mail:

Supplementary Materials

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 57 19 6
PDF Downloads 17 13 8
EPUB Downloads 0 0 0